RxDoctor Payments Data

Joseph Griffin, MD

Surgery · Baton Rouge, LANPI 1467642777

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (50.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Philips North America LLC accounts for 71.2% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2019 at $18,499 and has fallen 95.0% since, to $928 in 2025. Among surgery clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$32,739in general payments, 2019–2025

Across 265 payments — averaging $123.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$23K
  • Reflow Medical Inc$3K
  • Surmodics, Inc.$2K
  • Angiodynamics, Inc.$885
  • Silk Road Medical, Inc.$567
  • Avantec Vascular Corporation$563
  • plus $3K from 21 others
$67,352in research payments, 2019–2025

Across 12 payments — averaging $5612.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Surmodics, Inc.$67K

What the payments were for

  • Consulting fees$4,00012%
  • Speaking & faculty fees$16,40050%
  • Travel & lodging$4,04512%
  • Food & beverage$8,29425%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,739 in reported general payments places this provider in the 90th percentile of 381 surgery providers in Louisiana.

See all surgery providers in Louisiana

Medicare billing

Part B allowed, 2024
$82,045
Medicare patients
251
Services billed
610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban113$86,066
EliquisApixaban93$57,604
ClopidogrelClopidogrel Bisulfate59$313
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen37$164
Lorazepam12$8

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$233$86,066113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 381 surgery providers in Louisiana.

Other surgery in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →